Summary of the project

TreatER is a European Union-funded Research & Development project which aims to develop a novel treatment for Parkinson’s disease.

The main focus of the TreatER project is to conduct a first-in-human clinical study with intracerebrally administered CDNF protein in people with Parkinson’s disease using a neurosurgically implanted Drug Delivery System. The TreatER project was started in January 2017 and completion is anticipated in 2019.

Clinical study

The clinical study will recruit up to 20 people with Parkinson’s within a defined disease stage. For a patient, being part of this clinical study will mean more than 25 visits to the hospital over a period of 10-16 months. More information on the study can be found here.



The TreatER project will be implemented by a consortium of 11 members representing universities, university hospitals, a patient organisation as well as the pharmaceutical industry. Herantis Pharma Plc acts as the formal sponsor of the clinical study. Renishaw Plc, the developer of the Drug Delivery System, will be a co-sponsor of the clinical study. The three university hospitals responsible for patient treatments are Karolinska University Hospital and Skåne University Hospital in Sweden, and Helsinki University Hospital in Finland. In addition, the Universities of Helsinki and Oxford will together conduct non-clinical research related to the goals of the TreatER project.


  • Intrastriatally infused exogenous CDNF is endocytosed and retrogradely transported to substantia nigra
  • Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential
  • Chronic, intermittent convection-enhanced delivery devices.